Patent US2419693A successfully refreshed from Google Patents.
Patent EP0327180A2 successfully refreshed from Google Patents.
EP0327180A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
Assignee: MicroGeneSys Inc
•
Filing: 1989-02-02
•
Granted: —
•
Expires: 2009-02-02
Abstract
Abstract An Acquired Immunodeficiency Syndrome (AIDS) vaccine containing the Human Immunodeficiency Virus, Type-1 (HIV-1) envelope proteins is produced from cloned HIV-1 envelope genes in a baculovirus-inset cell vector system. The recombinant HIV-1 proteins are purified, assembled into particles and then adsorbed on an aluminum phosphate adjuvant. The resulting adsorbed recombinant HIV-1 virus envelope protein formulation is highly immunogenic in animals and elicits antibodies which bind to the HIV-1 virus envelope and neutralize the infectivity of the virus in in vitro tests.
Inventors
- 👤 Gale E. Smith
- 👤 Mark A. Cochran
- 👤 Franklin Volvovitz
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-02 23:39
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; C07; C07K; C07K14/00; C07K14/005; A61K; A61K38/00; A61K39/00; C12N2710/00; C12N2710/00011; C12N2710/14011; C12N2710/14111; C12N2710/14141; C12N2710/14143; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16211; C12N2740/16222; C12N2740/16234
Claims Analysis
Total Claims: 43
Claim 1
Independent Claim
6 words
Undenatured or native HIV-1 envelope protein.
Claim 2
Dependent Claim
6 words
Undenatured or native HIV-1 envelope protein.
Claim 3
Dependent Claim
10 words
Recombinant undenatured or native HIV-1 envelope protein of Claim 1.
Claim 4
Dependent Claim
11 words
Substantially biologically pure HIV-1 envelope protein in accordance with Claim 1.
Claim 5
Dependent Claim
22 words
Substantially biologically pure HIV-1 envelope protein in accordance with Claim 1 of a purity and quality useful as a vaccine for humans.
Claim 6
Dependent Claim
10 words
Substantially biologically pure gp160 protein in accordance with Claim 1.
Claim 7
Dependent Claim
22 words
Recombinant substantially pure HIV-1 envelope protein in accordance with Claim 1 of a purity and quality useful as a vaccine for humans.
Claim 8
Dependent Claim
17 words
A substantially non-pyrogenic vaccine composition containing a protein in accordance with Claim 1 together with an adjuvant.
Claim 9
Dependent Claim
14 words
A composition in accordance with Claim 7 wherein said adjuvant is particle-form aluminum phosphate.
Claim 10
Dependent Claim
14 words
A composition in accordance with Claim 7 wherein said adjuvant is particle-form aluminum hydroxide.
Claim 11
Dependent Claim
27 words
A composition for the treatment of acquired immunodeficiency syndrome (AIDS) compris ing a minor amount of a protein in accordance with Claim 1 together with a carrier.
Claim 12
Dependent Claim
9 words
gp160 HIV-1 envelope protein in accordance with Claim 1.
Claim 13
Dependent Claim
10 words
Recombinant gp160 HIV-1 envelope protein in accordance with Claim 1.
Claim 14
Dependent Claim
14 words
A recombinant DNA molecule for expressing HIV-1 envelope protein in accordance with Claim 1.
Claim 15
Dependent Claim
17 words
A DNA molecule of Figs. 4a-4k herein for expressing HIV-1 envelope protein in accordance with Claim 1.
Claim 16
Dependent Claim
17 words
A recombinant DNA molecule containing the DNA sequence for expressing the HIV-1 envelope protein of Claim 1.
Claim 17
Dependent Claim
19 words
A recombinant DNA molecule in accordance with Claim 15 containing a DNA sequence for expressing gp160 HIV-1 envelope protein.
Claim 18
Dependent Claim
8 words
A DNA molecule in accordance with AC3046 herein.
Claim 19
Dependent Claim
8 words
A DNA molecule in accordance with AC3046 herein.
Claim 20
Dependent Claim
22 words
Substantially biologically pure undenatured or native HIV-1 envelope protein in accordance with Claim 1 recovered after expression in a host insect cell.
Claim 21
Dependent Claim
15 words
Substantially biologically pure undenatured or native gp160 HIV-1 envelope protein in accordance with Claim 18.
Claim 22
Dependent Claim
19 words
Recombinant substantially biologically pure undenatured or native HIV-1 envelope protein expressed by Ac3046 herein in accordance with Claim 18.
Claim 23
Dependent Claim
27 words
The recombinant DNA molecule Ac3046 herein in accordance with Claim 17 for the expression of undenatured or native gp160 envelope protein of HIV-1 in an insect cell.
Claim 24
Dependent Claim
28 words
A method of treating a human patient suffering from AIDS which comprises administering to the patient a therapeutically effective amount of a protein in accordance with Claim 1.
Claim 25
Dependent Claim
26 words
A method for preventing AIDS in a human which comprises administering to said human an effective prophylactic amount of a protein in accordance with Claim 4.
Claim 26
Independent Claim
56 words
A method of recovering and purifying recombinant HIV-1 envelope protein material expressed in a cell which comprises after expression of said protein material recovering and washing the cells, lysing the cells, subjecting the resulting lysate to a lectin affinity chromatography followed by gel filtration chromatography and dialysis and recovering the resulting purified HIV-1 envelope protein material.
Claim 27
Independent Claim
56 words
A method of recovering and purifying recombinant HIV-1 envelope protein material expressed in a cell which comprises after expression of said protein material recovering and washing the cells, lysing the cells, subjecting the resulting lysate to a lectin affinity chromatography followed by gel filtration chromatography and dialysis and recovering the resulting purified HIV-1 envelope protein material.
Claim 28
Dependent Claim
42 words
A method in accordance with Claim 24 wherein said cells containing the to-be-recovered HIV-1 envelope protein material therein are subjected to washing in a buffer solution containing 50 nM Tris buffer at a pH 7.5 and 1nM EDTA and 1% Triton X-100.
Claim 29
Dependent Claim
36 words
A method in accordance with Claim 24 wherein cells lysis is carried out by sonication in a 50 nM Tris buffer at a pH in the range about 8.0-8.5 and 4% deoxycholate and 1% beta mercaptoethanol.
Claim 30
Dependent Claim
20 words
A method in accordance with Claim 24 wherein said gel filtration is carried out to a column containing Sephacryl resin.
Claim 31
Dependent Claim
18 words
A method in accordance with Claim 24 wherein said lectin affinity chromatography is carried out employing lentil lectin.
Claim 32
Dependent Claim
28 words
A method in accordance with Claim 24 wherein the resulting recovered purified HIV-1 envelope protein material is agglomerated or assembled into particles of about ≧ 2,000,000 molecular weight.
Claim 33
Dependent Claim
15 words
A method in accordance with Claim 24 wherein said HIV-1 envelope protein material is gp160.
Claim 34
Dependent Claim
30 words
A method in accordance with Claim 24 wherein said HIV-1 envelope protein material is gp160 which is agglomerated or assembled into particles having a molecular weight of about ≧ 2,000,000.
Claim 35
Dependent Claim
25 words
Undenatured or native HIV-1 envelope protein material in accordance with Claim 1 in finely divided particle-form and having a molecular weight of about ≧ 2,000,000.
Claim 36
Dependent Claim
18 words
Undenatured or native HIV-1 envelope protein material in accordance with Claim 32 wherein said protein material is gp160.
Claim 37
Dependent Claim
22 words
Undenatured or native HIV-1 envelope protein material in accordance with Claim 1 having a substantially spherical particle-form in the range about 30-100nM.
Claim 38
Dependent Claim
18 words
Undenatured or native HIV-1 envelope protein material in accordance with Claim 1 wherein said protein material is gp160.
Claim 39
Dependent Claim
30 words
An immunogen composition comprising undenatured or native HIV-1 envelope protein material complexed with alum wherein said protein material is present therein at a concentration of about 40µg/ml of said composition.
Claim 40
Dependent Claim
30 words
An immunogen composition comprising undenatured or native HIV-1 envelope protein material complexed with alum wherein said protein material is present therein at a concentration of about 40µg/ml of said composition.
Claim 41
Independent Claim
24 words
A method of complexing HIV-1 envelope protein material with alum wherein said protein is complexed with said alumn at a pH of about 7.0-7.2.
Claim 42
Independent Claim
24 words
A method of complexing HIV-1 envelope protein material with alum wherein said protein is complexed with said alumn at a pH of about 7.0-7.2.
Claim 43
Dependent Claim
15 words
A method in accordance with Claim 37 wherein said HIV-1 envelope protein material is gp160.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.